In breast cancer cells, treatment with the demethylating agent 5-aza-2-deoxycytidine led to increased expression of MCAM at both the mRNA and protein levels, indicating that hypermethylation of the MCAM promoter represses its transcription [121]. This evidence concerns the gene MCAM and breast carcinoma.